Nanotechnology and its medical applications: revisiting public policies from a regulatory perspective in Australia

Author:

Solaiman S.M.1,Yamauchi Yusuke2,Kim Jung Ho2,Horvat Joseph2,Dou Shi Xue2,Alici Gursel3,Ooi Lezanne4,Martinac Boris5,Shiddiky Muhammad J.A.6,Gopalan Vinod7,Hossain Md Shahriar A.2

Affiliation:

1. School of Law, University of Wollongong, Northfields Ave, Wollongong, New South Wales 2522, Australia

2. Australian Institute for Innovative Materials (AIIM), University of Wollongong, Wollongong, New South Wales, Australia

3. School of Mechanical, Materials, Mechatronic and Biomedical Engineering, and ARC Centre of Excellence for Electromaterials Science, University of Wollongong, NSW 2522, Australia

4. Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Wollongong, New South Wales 2522, Australia

5. Victor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia; and St Vincent’s Clinical School, The University of New South Wales, Darlinghurst, UNSW 2010, Australia

6. School of Natural Sciences & Queensland Micro & Nanotechnology Centre (QMNC), Griffith University (Nathan Campus), QLD 4111, Australia

7. School of Medicine and Cancer Molecular Pathology Laboratory in Menzies Health Institute Queensland, Griffith University Gold Coast, Australia

Abstract

AbstractNanobiotechnology is an immensely potential invention, which is expected to bring about revolutionary changes in many aspects of essential human needs including medical treatments and foods. Although the technology has passed through its embryonic stage, its medical applications in preparing and delivering drugs to target cells of human bodies to cure incurable diseases are still under scientific scrutiny. A 2007 study suggests that Australia needs to have a review of its regulatory framework for nanotechnology by 2017. This article examines the current regulation of nanotechnology and its medical applications in Australia, and observes that it would be premature to impose any stringent regulation at this stage on medical experimentations. We are of the view that an excessively precautionary policy may hinder further research, which is critical to discovering the benefit and harm with certainty. Hence, in the greater interest of the facilitation of research and affirmation of benefits of this technology, we recommend that adopting a hybrid regulatory method composed of self-regulation and accommodating government regulation would be an appropriate policy approach to the regulation of nanobiotechnology. We also accept the need for a set of internationally harmonized policy principles to guide our actions in relation to this technology.

Publisher

Walter de Gruyter GmbH

Subject

Surfaces, Coatings and Films,Process Chemistry and Technology,Energy Engineering and Power Technology,Biomaterials,Medicine (miscellaneous),Biotechnology

Reference86 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3